Who We Are


NanoValent has so far formally developed three NanoMod™ candidates: NV101, NV102 and NV103. These first NVP/NanoMod™ candidates (NV101 (Doxorubicin-anti-CD99), NV102 (Doxorubicin-anti-CD19) and NV103 (Irinotecan-anti-CD99) are approaching phase 1 and validating programs in Ewing sarcoma (with NV101 and NV103) is underway. A further program in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is also envisaged with NV102.

Our technology promises to enables significant enhancement of the performance of therapeutic agents. For example, NV102 increases tumor-killing efficacy 10-12 fold in vitro, compared to untargeted NanoMod™ with Doxorubicin and almost 40 fold versus conventional Doxorubicin. With NV101 the enhancement seen has been even greater, 40 fold versus commercially available Doxo-liposomes and 80 fold versus Doxorubicin. We are already seeing similar, perhaps greater, potential of enhanced power and control in other potential NV candidates as we explore new therapeutic and targeting combinations. Once we achieve basic clinical validation NanoValent will progress as a company able to apply NanoMod™ to various challenges, both in oncology and beyond.


Timothy Enns


Mr Enns is President and Chief Executive Officer of NanoValent. Mr. Enns has over 30 years experience in leadership roles within various Pharmaceutical and Biotechnology companies. Prior to NanoValent he held senior executive roles at KineMed Inc, Astex Pharmaceuticals, Inc (now Otsuka) and Sequus Pharmaceuticals. Mr. Enns management roles have included Business Development, Corporate Communications and Investor Relations, Marketing and Sales. His prior experience includes most aspects of cancer therapeutic commercialization from start up through launch and partnering. Prior to Sequus he held senior positions at Trilex, Syncor, MGI Pharma and Upjohn. He has a BS in Nutritional Science & Biochemistry from UC Davis.

Jon Nagy, PhD

Chief Scientific Officer

Dr. Nagy is co-founder of NanoValent and received his PhD in synthetic organic chemistry from Iowa State University in 1983, and completed doctoral training at UC Berkeley. In 1990, Dr. Nagy joined Lawrence Berkeley National Laboratory where he generated seven issued patents and 15 scientific publications, including a paper in Science related to polymer films and nanoparticles. In 1999, Dr. Nagy joined LigoCyte Pharmaceuticals as Director of Chemistry and Nanoparticle research. He is now a full time member of NanoValent.

Timothy Triche MD, PhD

Chief Medical Officer

Dr. Triche is co-founder of NanoValent and is board certified in pathology and is on the staff of Children’s Hospital Los Angeles and a faculty at the University of Southern California. His expertise centers on the field of tumor cell biology. Dr. Triche has been a principle and founder in several publicly traded companies that have raised a total of $70M in public markets. He was co-founder of OncorMed, which was sold to Gene Logic (GLGC).

Mark Lewis

Chief Operating Officer

Mr. Lewis has 35 years international experience in the pharmaceutical industry; 25 years with companies including Amersham International (now part of GE), Farmitalia (now Pfizer), Chiron (now Novartis), Groupe Servier, Ascalon and SuperGen (now Otsuka) in various senior commercial and operational roles and 10 years as a management consultant (including Quintiles, Hill & Knowlton) for a spectrum of pharmaceutical and biotechnology clients. With an honors degree in biochemistry and secondary business qualifications, Mr. Lewis has an extensive background in strategic marketing, project management, business development and operations gained in many therapeutic areas but primarily oncology.

Clinical & Operational Collaborators: (available via CDA)


Advisory Board: (in development)


Company Financing

NanoValent has progressed so far thanks to various NIH, NCI and NSF grants for oncology, imaging and vaccine projects, founder investment and its first external seed investment during 2017. NanoValent is now seeking further external private investment to enable pre-IND activities and then once an IND is achieved will seek further funding to enable a clinical POC phase.

Company News

NanoValent Appoints Timothy Enns as Chief Executive Officer, January 11, 2017Read More

NanoValent Announces CHLA agreement and completion of First Wave of Financing, October 10, 2017Read More